Elevated serum RANTES levels in patients with ovarian cancer correlate with the extent of the disorder

Tsukishiro, Sami; Suzumori, Nobuhiro; Nishikawa, Hiroshi; Arakawa, Atsushi; Suzumori, Kaoru

doi:10.1016/j.ygyno.2006.01.029

Cited by 53 publications

(39 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CCR5 expression on T regs isolated from ovarian cancer patients was significantly higher than that of T regs isolated from healthy volunteers. Furthermore, CCL5 has been reported to be elevated in ovarian cancer patients [50], which might account for the accumulation of T regs in the tumour microenvironment of ovarian cancer patients.…”

Section: Discussionmentioning

confidence: 99%

Ovarian cancer stem cells promote tumour immune privilege and invasion via CCL5 and regulatory T cells

You

et al. 2017

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SummaryEmerging evidence indicates a link between the increased proportion of regulatory T cells (T regs ) and reduced survival in patients who have been diagnosed with cancer. Cancer stem cells (CSCs) have been indicated to play a vital role in tumour initiation, drug resistance and recurrence. However, the relationship between T regs and CSCs remains largely unknown. Here, we sorted out ovarian cancer stem-like side population (SP) cells and CD133 1 cells to investigate the influence of ovarian CSCs on T regs . Among the various immune-related molecules that we assessed, C-C motif chemokine ligand 5 (CCL5) was the most elevated in ovarian CSCs relative to that in the non-CSCs. The expression of its receptor, C-C motif chemokine receptor 5 (CCR5), was also increased on the surface of T regs in ovarian cancer patients. This receptor-ligand expression profile indicated that ovarian CSCs recruit T regs via CCL5-CCR5 interactions. We further assessed the expression of interleukin (IL)-10 in T regs cultured with different cancer cells. For the first time, to our knowledge, our findings describe the relationship between ovarian CSCs and T regs , and demonstrated that these two cell populations co-operate to promote tumour immune tolerance and enhance tumour progression.

show abstract

Section: Discussionmentioning

confidence: 99%

Ovarian cancer stem cells promote tumour immune privilege and invasion via CCL5 and regulatory T cells

You

et al. 2017

Clinical and Experimental Immunology

View full text Add to dashboard Cite

show abstract

“…Previous studies have demonstrated that high tissue and plasma CCL5 levels are correlated with advanced breast cancer and could be used as a prognostic indicator for breast, cervical and gastric cancers (6,35,36). Serum CCL5 may be useful in differentiating benign ovarian tumors from malignancy (37). We examined ovarian cancer tissue excised from a patient prior to chemotherapy and relapsed tissues after four courses of standard chemotherapy, CCL5 expression was significantly increased after exposure to chemotherapy, as demonstrated by IHC (Fig.…”

Section: Expression and Clinicopathological Characteristics Of Ccl5mentioning

confidence: 99%

Cisplatin-induced CCL5 secretion from CAFs promotes cisplatin-resistance in ovarian cancer via regulation of the STAT3 and PI3K/Akt signaling pathways

Zhou

Sun

et al. 2016

International Journal of Oncology

View full text Add to dashboard Cite

Abstract. Currently, acquired resistance to cisplatin (DDP) is a substantial obstacle to reducing the morbidity and mortality due to ovarian malignant tumors. Nevertheless, cisplatin plays a vital role in killing the tumor cells while it may also be a 'primer' involved in chemotherapy resistance. We found that the cisplatin-induced chemokine (C-C motif) ligand 5 (CCL5) secretion derived from cancer-associated fibroblasts (CAFs) promoted ovarian cancer cell resistance to cisplatin. Via a cytokine chip assay, we identified a spectrum of secreted proteins that were derived from the CAFs through cisplatin-induced treatment. Among these, CCL5 significantly attenuated the cytotoxic effect of cisplatin chemotherapy in vitro and in vivo. Additionally, CCL5 expression was also detected in 62 serous ovarian cancer patient tissue specimens using IHC, and the results demonstrated that chemotherapy resistant patients displayed higher expression of CCL5 than the chemo-sensitive patients (P<0.05). Mechanistically, we found that CCL5 notably increased STAT3 and Akt phosphorylation levels in ovarian cancer cells. These results indicated that cisplatininduced CCL5 secretion derived from the CAFs may promote cisplatin resistance, which was mediated by regulation of the STAT3 and PI3K/Akt signal pathways.

show abstract

“…75 In a Japanese study, it was found that serum CCL5 concentration was significantly elevated in the ovarian cancer patients compared to the benign ovarian cyst patients as controls correlating with the stage of disease and the extent of residual tumor mass. 76 Mantle cell lymphomas acquire increased expression of CCL4, CCL5 and 4-1BB-L, which are implicated in cell survival. 77 CCL5 expression is a predictor of survival in stage I lung adenocarcinoma.…”

Section: Ccl5 and Other Cancersmentioning

confidence: 99%

CCL5 as a potential immunotherapeutic target in triple-negative breast cancer

Zhang

Kim

et al. 2013

Cell Mol Immunol

View full text Add to dashboard Cite

Breast cancer (BC) is a leading cause of mortality among women in the world. To date, a number of molecules have been established as disease status indicators and therapeutic targets. The best known among them are estrogen receptor-a (ER-a), progesterone receptor (PR) and HER-2/neu. About 15%-20% BC patients do not respond effectively to therapies targeting these classes of tumor-promoting factors. Thus, additional targets are strongly and urgently sought after in therapy for human BCs negative for ER, PR and HER-2, the so-called triple-negative BC (TNBC). Recent clinical work has revealed that CC chemokine ligand 5 (CCL5) is strongly associated with the progression of BC, particularly TNBC. How CCL5 contributes to the development of TNBC is not well understood. Experimental animal studies have begun to address the mechanistic issue. In this article, we will review the clinical and laboratory work in this area that has led to our own hypothesis that targeting CCL5 in TNBCs will have favorable therapeutic outcomes with minimal adverse impact on the general physiology.

show abstract

Elevated serum RANTES levels in patients with ovarian cancer correlate with the extent of the disorder

Cited by 53 publications

References 12 publications

Ovarian cancer stem cells promote tumour immune privilege and invasion via CCL5 and regulatory T cells

Ovarian cancer stem cells promote tumour immune privilege and invasion via CCL5 and regulatory T cells

Cisplatin-induced CCL5 secretion from CAFs promotes cisplatin-resistance in ovarian cancer via regulation of the STAT3 and PI3K/Akt signaling pathways

CCL5 as a potential immunotherapeutic target in triple-negative breast cancer

Contact Info

Product

Resources

About